6-Mercaptopurine treats certain cancers effectively. Doctors prescribe it mainly for acute lymphoblastic leukemia (ALL).
First, it acts as an antimetabolite. The drug mimics purine bases in DNA synthesis. Therefore, cancer cells incorporate it during replication.
Moreover, 6-MP disrupts DNA and RNA production. It forms fraudulent nucleotides. As a result, cell division stops in rapidly growing leukemia cells.
Additionally, the body converts 6-MP into active metabolites. Thioguanine nucleotides become the main toxic forms. Consequently, these metabolites cause chain termination in DNA strands.
Furthermore, doctors combine it with other drugs. It works well in maintenance therapy for ALL. Thus, remission lasts longer in children and adults.
However, toxicity requires careful monitoring. Bone marrow suppression occurs commonly. Therefore, doctors check blood counts regularly.
Next, hepatotoxicity appears as another side effect. Elevated liver enzymes signal damage. So, patients need frequent liver function tests.
Moreover, TPMT enzyme activity affects dosing. Low TPMT levels increase toxicity risk. Thus, genetic testing guides safe dosing.
In addition, mercaptopurine causes nausea and vomiting. Patients often take it with food. Consequently, gastrointestinal upset decreases.
Despite challenges, 6-MP improves survival rates significantly. It remains a cornerstone in ALL protocols. Overall, proper use saves many lives.